The treatment combines a new drug, inavolisib, with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®) . Inavolisib, which targets PIK3CA mutations, appears to be a ...
My group focuses on understanding cell signaling pathways primarily linked with the ubiquitin and autophagy systems and frequently altered in diseases, including neurodegenerative disease. To this end ...